Repros Therapeutics Inc. (the “Company,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.
Company profile
Ticker
RPRX
Exchange
Website
CEO
Larry M. Dillaha
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Repros Therapeutics Inc, Zonagen Inc
SEC CIK
Corporate docs
IRS number
760233274
Latest filings (excl ownership)
15-12B
Securities registration termination
9 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
25-NSE
Exchange delisting
31 Jan 18
8-K
Completion of Acquisition or Disposition of Assets
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
Latest ownership filings
SC 13G/A
Repros Therapeutics Inc.
14 Feb 19
SC 13G/A
Repros Therapeutics Inc.
13 Feb 18
4
Katherine Anderson
31 Jan 18
4
Michael Wyllie
31 Jan 18
4
PATRICK FOURTEAU
31 Jan 18
4
DANIEL F CAIN
31 Jan 18
4
Saira Ramasastry
31 Jan 18
4
Nola E Masterson
31 Jan 18
SC 13G
Repros Therapeutics Inc.
2 Jan 18
SC 13G/A
Repros Therapeutics Inc.
2 Jan 18
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|